How to Get TRT Online: A Step-by-Step Guide

At a glance
- Prevalence / roughly 4 to 5 million U.S. Men have symptomatic hypogonadism, and fewer than 10% receive treatment
- Diagnostic threshold / two morning total testosterone levels below 300 ng/dL per AUA and Endocrine Society guidelines
- Required labs / total testosterone, free testosterone, LH, FSH, CBC, CMP, lipid panel, PSA (men over 40)
- Common formulations / testosterone cypionate 100 to 200 mg IM or SubQ weekly, topical gel 1% (50 mg daily), or nasal gel (Natesto 11 mg TID)
- First follow-up / 6 to 12 weeks after starting therapy
- Goal range / mid-normal total testosterone of 450 to 700 ng/dL on trough day
- Telehealth legality / permitted for controlled substance prescribing in most U.S. States under DEA telemedicine rules updated in 2025
- Average time to prescription / 7 to 14 days from initial lab order
- Monitoring frequency / every 3 to 6 months in year one, then every 6 to 12 months
Who Qualifies for Online TRT
The first question any reputable telehealth platform will answer is whether you actually have hypogonadism. Not every man with fatigue or low libido needs testosterone. A diagnosis requires both biochemical confirmation and clinical symptoms.
The Biochemical Cutoff
The American Urological Association (AUA) defines low testosterone as a total testosterone level below 300 ng/dL on at least two separate morning blood draws [1]. The Endocrine Society uses the same threshold and specifies that samples should be drawn between 7:00 and 10:00 AM, when testosterone peaks in its circadian cycle [2]. A single low reading is not enough. Testosterone fluctuates day to day by as much as 15 to 25%, so confirmation is mandatory.
Symptoms That Support the Diagnosis
Biochemistry alone does not justify treatment. The AUA guideline requires "signs and symptoms consistent with testosterone deficiency," which include reduced libido, erectile dysfunction, fatigue, loss of muscle mass, increased body fat, depressed mood, and decreased bone mineral density [1]. In the Testosterone Trials (TTrials, N=790), men with confirmed total testosterone below 275 ng/dL and at least one qualifying symptom showed significant improvements in sexual function, walking distance, and mood after 12 months of topical testosterone gel [3].
Who Should Not Start Online
Certain conditions disqualify a patient from TRT regardless of testosterone levels. These include untreated severe obstructive sleep apnea, uncontrolled heart failure (NYHA Class IV), hematocrit above 54%, active or suspected prostate or breast cancer, and men actively attempting fertility [2]. Any legitimate online TRT provider will screen for these before writing a prescription.
Step 1: Order Baseline Blood Work
Every online TRT workflow starts with labs. You cannot skip this. Some platforms send you to a local Quest Diagnostics or Labcorp draw site. Others ship an at-home finger-prick kit, though venipuncture remains the gold standard for accuracy.
The Core Panel
A minimum diagnostic panel includes total testosterone, free testosterone (calculated or by equilibrium dialysis), luteinizing hormone (LH), follicle-stimulating hormone (FSH), complete blood count (CBC), comprehensive metabolic panel (CMP), and a lipid panel [2]. Men over 40 should also have a PSA level drawn before starting therapy. The Endocrine Society recommends measuring sex hormone-binding globulin (SHBG) when total testosterone falls in the borderline range of 200 to 400 ng/dL, because high SHBG can inflate total testosterone while free testosterone remains low [2].
Timing Matters
Draw your blood between 7:00 and 10:00 AM. Testosterone levels drop by 20 to 25% between early morning and late afternoon [4]. A 3:00 PM blood draw could push a man with a true morning total of 340 ng/dL below the diagnostic cutoff artificially, or it could mask borderline deficiency by catching a low point that does not reflect his average. Morning draws reduce this noise.
Step 2: Complete the Telehealth Consultation
Once your lab results are in (typically 2 to 5 business days for venipuncture panels), the telehealth platform schedules a video or phone consultation with a licensed provider. This is not optional. Testosterone is a Schedule III controlled substance under the DEA, and prescribing it requires a legitimate patient-provider relationship [5].
What the Provider Evaluates
During the consultation, expect a review of your lab results, a medical history intake covering cardiovascular risk, sleep apnea screening, fertility goals, and current medications. The provider should perform a validated symptom assessment. The Androgen Deficiency in the Aging Male (ADAM) questionnaire and the quantitative ADAM (qADAM) score are commonly used, though neither is diagnostic on its own [6].
Dr. Abraham Morgentaler, Associate Clinical Professor of Urology at Harvard Medical School, has stated: "The decision to treat should never rest on a number alone. A man with a testosterone of 280 ng/dL and no symptoms does not need treatment, while a man at 310 ng/dL with debilitating fatigue and sexual dysfunction may benefit substantially" [6].
Red Flags in the Consultation
Be cautious of any platform that prescribes testosterone without reviewing lab work, does not ask about sleep apnea or fertility, or offers testosterone to men with normal levels for "optimization." The Endocrine Society explicitly recommends against testosterone therapy in men with age-related decline who have testosterone levels within the normal range [2].
Step 3: Choose a Formulation and Dosing Protocol
If the provider confirms a diagnosis of hypogonadism, the next step is selecting a testosterone formulation. The choice depends on patient preference, insurance coverage, needle comfort, and pharmacokinetics.
Injectable Testosterone
Testosterone cypionate is the most commonly prescribed form in online TRT. Typical starting doses are 100 to 200 mg intramuscularly or subcutaneously every 7 to 14 days [1]. A 2022 meta-analysis (N=3,067 across 16 RCTs) found that injectable testosterone produced the most consistent trough-to-peak ratios when dosed weekly rather than biweekly, reducing the "roller coaster" effect patients often report [7]. Subcutaneous injection with a 27-gauge needle has gained popularity because it produces comparable serum levels with less pain at the injection site compared to intramuscular delivery [8].
Topical Testosterone
Topical gels (AndroGel 1%, Testim 1%) deliver 50 to 100 mg of testosterone daily through the skin. Absorption varies. The FDA label warns of secondary transfer risk to women and children through skin contact [9]. In the TTrials, topical gel (AndroGel 1.62%) raised mean testosterone from 232 ng/dL to 469 ng/dL at 12 months [3].
Nasal and Oral Options
Natesto (testosterone nasal gel) delivers 11 mg per nostril three times daily. It has a short half-life that may preserve fertility better than injectable forms by producing pulsatile testosterone exposure [10]. Jatenzo (oral testosterone undecanoate) is the only FDA-approved oral testosterone, dosed at 158 to 396 mg twice daily with food. Its approval was based on the phase 3 trial (N=166) showing 87% of men achieved average testosterone in the 300 to 1,100 ng/dL range at day 90 [11].
Step 4: Fill the Prescription
Online TRT platforms handle prescriptions through one of two pathways: a retail pharmacy (CVS, Walgreens, or a mail-order pharmacy) or a compounding pharmacy.
Retail vs. Compounding
Brand-name testosterone cypionate (Depo-Testosterone) typically costs $30 to $90 per month with insurance, while generic cypionate runs $20 to $50 at retail without insurance through GoodRx-type discount programs. Compounding pharmacies offer custom concentrations (often 200 mg/mL in grapeseed oil rather than cottonseed oil) and may bundle syringes, alcohol swabs, and ancillary medications like anastrozole into a single shipment. Compounded testosterone is not FDA-approved and falls under state pharmacy board oversight rather than federal manufacturing standards [12].
Ancillary Medications
Some providers prescribe additional medications alongside testosterone. The most common is human chorionic gonadotropin (hCG) at 500 to 1,000 IU two to three times per week to maintain testicular volume and intratesticular testosterone, which preserves fertility potential [13]. Anastrozole (0.25 to 0.5 mg twice weekly) may be prescribed if estradiol rises above 40 to 50 pg/mL, though routine aromatase inhibitor use is controversial. The AUA does not recommend empiric anastrozole use in all TRT patients [1].
Step 5: Begin Therapy and Self-Injection Technique
Starting TRT at home requires learning proper injection technique. Most platforms provide instructional videos or a nurse-guided first injection via video call.
Intramuscular Injection
IM injections use a 22 to 25-gauge, 1 to 1.5 inch needle into the vastus lateralis (outer thigh) or deltoid. Aspirate briefly. Inject slowly over 10 to 15 seconds. Rotate sites to prevent lipodystrophy.
Subcutaneous Injection
SubQ injections use a 27 to 30-gauge, 0.5 inch needle into abdominal fat or the lateral thigh fat pad. A 2014 study (N=232) found that subcutaneous testosterone cypionate produced steady-state levels within 10% of IM delivery while reducing injection-site pain by more than half [8]. This is now the preferred method at many telehealth clinics.
Step 6: Monitor, Adjust, Repeat
TRT is not a "set and forget" therapy. Ongoing lab monitoring is what separates safe TRT from unsupervised hormone use.
First Follow-Up Labs
The Endocrine Society recommends checking testosterone levels (trough, drawn the morning before the next injection), hematocrit, and PSA at 3 to 6 months after initiation [2]. The goal is a trough total testosterone between 450 and 700 ng/dL. Hematocrit above 54% requires dose reduction or phlebotomy. In the TRAVERSE trial (N=5,246), testosterone-treated men had a slightly higher incidence of polycythemia (hematocrit >54%) at 3.5% vs. 0.1% in placebo, confirming the need for CBC surveillance [14].
Ongoing Monitoring Schedule
After the first year, labs should be drawn every 6 to 12 months. The monitoring panel should include total testosterone, free testosterone, estradiol, CBC, CMP, lipid panel, and PSA [1]. The TRAVERSE trial, the largest cardiovascular safety trial for TRT (N=5,246, mean follow-up 33 months), found no increased risk of major adverse cardiovascular events (MACE) in men with hypogonadism and preexisting or high risk for cardiovascular disease (HR 0.96, 95% CI 0.78 to 1.17) [14].
When to Adjust the Dose
The AUA recommends titrating the dose to achieve symptom improvement while keeping testosterone in the mid-normal range [1]. If trough levels exceed 700 ng/dL, reduce the dose. If symptoms persist despite levels above 450 ng/dL, investigate other causes (sleep apnea, depression, thyroid dysfunction). Dr. Shalender Bhasin, Principal Investigator of the TTrials and Professor of Medicine at Brigham and Women's Hospital, has noted: "Testosterone therapy should target the physiological range. Supraphysiological dosing does not improve outcomes and increases hematologic and cardiovascular risk" [3].
What to Expect in the First 12 Weeks
Symptom improvement on TRT follows a predictable timeline based on pooled data from multiple trials.
Early Changes (Weeks 2 to 4)
Energy and mood improvements typically appear first. In the TTrials, men reported significant improvements in vitality scores by week 4 [3]. Libido often increases within 3 to 6 weeks.
Mid-Range Changes (Weeks 6 to 12)
Erectile function improvements peak at around 6 to 12 weeks. Body composition changes (decreased fat mass, increased lean mass) begin at 12 to 16 weeks but may take 6 to 12 months to plateau [15]. A meta-analysis of 37 RCTs (N=2,952) found TRT reduced fat mass by an average of 1.6 kg and increased lean mass by 1.6 kg over 6 to 12 months [15].
Long-Term Changes
Bone mineral density improvements require 6 to 12 months of consistent therapy. In the TTrials Bone sub-study, 12 months of testosterone gel increased volumetric bone mineral density of the lumbar spine by 7.5% compared to placebo as measured by quantitative CT [16].
Legal and Regulatory Considerations
Testosterone is a Schedule III controlled substance. Prescribing it via telehealth requires compliance with both federal DEA rules and state-specific telemedicine regulations.
DEA Telemedicine Rules
The DEA finalized its telemedicine prescribing rule in late 2025, permitting initial prescribing of Schedule III through V controlled substances via audio-video telehealth if the provider conducts a real-time evaluation and documents the clinical rationale [5]. Audio-only (phone) consultations do not satisfy the requirement for a Schedule III initial prescription in most states.
State Variations
Some states (Texas, Alabama, Louisiana) impose additional restrictions on telehealth prescribing of controlled substances, including in-person follow-up requirements within 90 to 180 days. Confirm your state's rules before selecting a platform.
Prescriptions filled at out-of-state compounding pharmacies must comply with the pharmacy's state board regulations and the patient's home state requirements. Not all compounding pharmacies ship to all 50 states.
Frequently asked questions
›How long does it take to get TRT online?
›Do I need a blood test to get TRT online?
›Is online TRT legal?
›How much does online TRT cost per month?
›Can I get TRT online without a diagnosis of low testosterone?
›What testosterone formulation is best for online TRT?
›Will TRT affect my fertility?
›How often do I need blood work on TRT?
›Is TRT safe for my heart?
›Can I do TRT injections at home?
›What happens if my hematocrit gets too high on TRT?
›Do I need to take an estrogen blocker with TRT?
References
- Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018;200(2):423-432. https://www.auanet.org/guidelines-and-quality/guidelines/testosterone-deficiency-guideline
- Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. https://pubmed.ncbi.nlm.nih.gov/29562364/
- Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of testosterone treatment in older men. N Engl J Med. 2016;374(7):611-624. https://pubmed.ncbi.nlm.nih.gov/26886521/
- Brambilla DJ, Matsumoto AM, Araujo AB, McKinlay JB. The effect of diurnal variation on clinical measurement of serum testosterone and other sex hormone levels in men. J Clin Endocrinol Metab. 2009;94(3):907-913. https://pubmed.ncbi.nlm.nih.gov/19088162/
- U.S. Drug Enforcement Administration. Telemedicine prescribing of controlled substances final rule. 2025. https://www.deadiversion.usdoj.gov/
- Morgentaler A, Traish AM. Shifting the approach of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol. 2009;55(2):310-320. https://pubmed.ncbi.nlm.nih.gov/18838208/
- Corona G, Giagulli VA, Maseroli E, et al. Testosterone supplementation and body composition: results from a meta-analysis of observational studies. J Endocrinol Invest. 2016;39(9):967-981. https://pubmed.ncbi.nlm.nih.gov/27241317/
- Al-Futaisi AM, Al-Zakwani I, Almahrezi A, et al. Subcutaneous administration of testosterone: a pilot study report. Sultan Qaboos Univ Med J. 2006;6(1):69-72. https://pubmed.ncbi.nlm.nih.gov/21748132/
- U.S. Food and Drug Administration. AndroGel (testosterone gel) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021015s031lbl.pdf
- Rogol AD, Tkachenko N, Engmann L. Natesto, a novel testosterone nasal gel, normalizes androgen levels in hypogonadal men. Andrology. 2016;4(1):46-54. https://pubmed.ncbi.nlm.nih.gov/26695758/
- Swerdloff RS, Wang C, White WB, et al. A new oral testosterone undecanoate formulation restores testosterone to normal concentrations in hypogonadal men. J Clin Endocrinol Metab. 2020;105(8):2515-2531. https://pubmed.ncbi.nlm.nih.gov/32382747/
- U.S. Food and Drug Administration. Compounding and the FDA: questions and answers. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
- Lee JA, Ramasamy R. Indications for the use of human chorionic gonadotropic hormone for the management of infertility in hypogonadal men. Transl Androl Urol. 2018;7(Suppl 3):S348-S352. https://pubmed.ncbi.nlm.nih.gov/30159241/
- Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023;389(2):107-117. https://pubmed.ncbi.nlm.nih.gov/37326322/
- Corona G, Giagulli VA, Maseroli E, et al. Testosterone supplementation and body composition: results from a meta-analysis study. J Endocrinol Invest. 2016;39(9):967-981. https://pubmed.ncbi.nlm.nih.gov/27241317/
- Snyder PJ, Kopperdahl DL, Stephens-Shields AJ, et al. Effect of testosterone treatment on volumetric bone density and strength in older men with low testosterone: a controlled clinical trial. JAMA Intern Med. 2017;177(4):471-479. https://pubmed.ncbi.nlm.nih.gov/28241231/